 Aurinia Pharmaceuticals recently announced they have reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Both companies will dismiss their claims and counterclaims against each other. Following the settlement announcement, AUPH shares jumped up over 30, and have since climbed to around 6.75 per share. This settlement removes a significant overhang for the company and AUPH. 